Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Follitropin delta (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms RITA-1
  • Sponsors Ferring Pharmaceuticals

Most Recent Events

  • 27 Oct 2025 Primary endpoint (Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COS) has been met, according to Ferring Pharmaceuticals media release.
  • 27 Oct 2025 According to Ferring Pharmaceuticals media release, data from this trial data were presented at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) (October 25-29; San Antonio, Texas.
  • 27 Oct 2025 Results presented at Ferring Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top